drugset / Trial / NCT07038005
A Phase I Study of SPGL008 in Subjects With Advanced Malignant Tumors
Phase 1
Recruiting
96 enrolled
Shenyang Sunshine Pharmaceutical Co., LTD.
Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study includes two cohorts, respectively evaluating safety, tolerability and preliminary efficacy of intravenous and subcutaneous administration of SPGL008.
Timeline
- Start
- 2025-07-30
- Primary completion
- 2026-09-22
- Completion
- 2027-06-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SPGL008 | Unknown | — | Intravenous |